Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$152.64 USD
-2.40 (-1.55%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $152.80 +0.16 (0.10%) 7:06 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$152.64 USD
-2.40 (-1.55%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $152.80 +0.16 (0.10%) 7:06 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Zacks News
Top Stock Picks for the Week of October 29th
by Panel Of Zacks Experts
Our experts take a look at two good defensive plays.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
J&J Intends to Buy Residual Stake in Japanese Skincare Firm
by Zacks Equity Research
Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC
by Zacks Equity Research
The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines
by Zacks Equity Research
Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.
Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT
by Zacks Equity Research
Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.
Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $138.68, marking a -0.27% move from the previous day.
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet
Quiet Friday Session Caps Another Volatile Week in the Markets
by David Borun
Earnings and Geopolitical events contribute to another wild ride
Upcoming Tech Earnings to Watch: MSFT, AMZN, GOOGL
by Ryan McQueeney
More major tech reports will begin pouring in next week, and Wall Street will be hoping for strength from the sector's leaders. Here's a close look at a few of the major tech earnings reports due out in the coming days.
Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
by Ryan McQueeney
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
Top-Ranked Healthcare ETFs for Long-Term Investors
by Neena Mishra
Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.
Stock Market News For Oct 17, 2018
by Zacks Equity Research
Wall Street rebounded on Tuesday as stocks surged across the board due to strong third-quarter 2018 earnings results and impressive economic data.
This Week's Most Spectacular Earnings Charts
by Tracey Ryniec
It doesn't get much better than these five big cap companies with their outstanding earnings surprise records and great earnings charts.
Will Tuesday's Earnings Reports Inspire a Stock Market Rebound?
by Ryan McQueeney
Ryan McQueeney recaps the morning's top pre-market earnings reports from Goldman Sachs, Morgan Stanley, and Johnson & Johnson. Later, he is joined by Zacks Strategist Dave Bartosiak to discuss upcoming reports from Netflix and IBM.
Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ
by Zacks Equity Research
Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ
Q3 Earnings Results Impress: GS, MS, UNH & More
by Mark Vickery
Q3 earnings reports are hitting the tape fast and furious at this hour. We will take this opportunity to summarize a handful of them.
J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the third quarter of 2018 and raises full-year forecast.
Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.99% and 2.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview
by Zacks Equity Research
JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview
Friday Bounce Ends a Volatile Week for Stocks
by David Borun
Interest rates fears fuel the biggest weekly decline in 7 months